Migraine Briefs

Prior exposure and response to triptans may not affect efficacy of ubrogepant


 

Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.

Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom ( Pinteraction based on odds ratio [OR] = .290) and absence of migraine-associated symptom ( Pinteraction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.

Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.

Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.

Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089 .

Recommended Reading

Cutaneous allodynia prevalence comparable in patients with migraine and probable migraine
Migraine ICYMI
Real-world efficacy of candesartan as a preventive migraine treatment
Migraine ICYMI
Type of bariatric surgery influences likelihood of migraine remission
Migraine ICYMI
Eptinezumab shows long-term safety and tolerability in chronic migraine
Migraine ICYMI
Chronic migraine: Addition of CGRP-targeted mAb to onabot further improves headache control
Migraine ICYMI
Patients with migraine more likely to report comorbidities and health problems
Migraine ICYMI
Migraine: Women have a higher prevalence of neck pain and cutaneous allodynia
Migraine ICYMI
Green light puts the stop on migraine
Migraine ICYMI
Ubrogepant safety and efficacy not affected by triptan therapy
Migraine ICYMI
Migraine: Anti-CGRP mAbs beneficial in partial and nonresponders to onabotulinumtoxinA
Migraine ICYMI